The main purpose of the present article is reactivity and stability properties study of the antagonist compound esketamine and analyzing of its binding to the noncompetitive N-methyl-D-aspartate receptor subunits (NR1, NR2A, NR2B and NR2D). In first step, the molecular structure of esketamine was optimized using density functional theory (DFT) method at B3YP/6-311++G(d,p) level of theory. The reactivity and stability properties of the title medicinal compound were studied by global reactivity indices. The computational data showed the molecule is stable and has low tendency to interact with residues of the biomolecules like receptors and proteins. Secondly, the molecule binding to the receptors were analyzed by molegro virtual docker (MVD) program. Our computations indicated that the compound asserts its pharmacological effects mainly through interactions with NR2B receptors and the NR2B residues containing Gly [A] 128, His [A] 127, Gly [A] 264, Tyr [A] 282, Ser [A] 131, Asp [A] 265, Ser [A] 260 and Met [A] 132 are the main amino acids involved in the ligand-receptor complex formation.
Introduction
Major depressive disorder or MDD is a serious neurological condition that afflicts almost 300 million people around the world. Over the years, various classes of antidepressants have been developed. Although the efforts to manage MDD have been fruitful in many cases, still about 30% of patients show resistance to the available drugs. As a result, the attempt to find alternative therapies for treatment-resistant depression (TRD) has been of particular interest in the past few years [1] .
Despite the prominent use of monoamine systems such as serotonin, dopamine and noradrenaline systems in modern medicine and their general efficacy in treating MDD, the glutamate system have come into focus in hopes of achieving better and more effective outcomes [2] . The glutamate system is proved to be one of the key neurological pathways contributing to depression prevalence in patients. The analysis of plasma, cerebrospinal fluid and the brain of MDD patients show elevated levels of glutamate. Furthermore, the overexpression of NMDA receptors in MDD patients have been reported in a series of studies [3] . Ketamine is an NMDA receptor antagonist commonly used as an anesthetic drug.
In certain doses Ketamine has fast-acting and powerful antidepressant properties [4] . Ketamine is a racemic mixture consisting of two enantiomeric isomers Rketamine and S-ketamine (also known as Esketamine).
Esketamine has been observed to possess higher affinity towards NMDA receptors and is less likely to induce unwanted effects compared with racemic Ketamine [5] .
Furthermore, Ketamine is mainly administered via infusion which greatly affects the ease of drug use in patients. On the other hand, a period of weeks to months should pass before the beneficial effects of first-line antidepressants such as SSRIs are witnessed therefore; the rapid onset of action in Esketamine is of particular importance [6] . The antidepressant effects of intranasal Esketamine take place after only 2 to 24 hours of its single dose administration [7] . The intranasal administration of Esketamine as well as efficacy and safety of this drug as a complementary therapy alongside oral antidepressants in treatment of TRD have been thoroughly evaluated [8] and in 2019, Spravato ® the nasal spray of Esketamine received its FDA approval. Intranasal rout of administration not only facilitates the use of drug by patients but also remarkably increases drug bioavailability through bypassing first pass metabolism. The improved bioavailability further results in lower dose consumption and limitation of adverse effects [9] . Esketamine's comparatively low molecular weight makes it suitable in intranasal delivery due to acceptable nasal mucosa absorption [10] .
Although the previous studies provide detailed information about efficacy and safety of Esketamine in treating TRD and a general outlook on the mechanism of its effect on NMDA receptors, the exact structural and molecular drug-receptor interaction and the affected NMDA subunits are still unclear. In the present study, we analyzed the exact molecular mechanisms involved in interaction of Esketamine with NMDA receptor subtypes N1, NR2A, NR2B and NR2D, using molecular docking methods and computational chemistry. Moreover, the pharmacokinetic and biological behavior of the titled drug was determined using SwissADME web tool [11] [12] [13] [14] .
Computational methods
Today, drug design and the determination of its physicochemical properties are one of the major issues of the medicinal chemistry. Calculating these properties is performed by computational chemistry. This field of chemistry is divided into two issues: quantum mechanics (QM) and molecular dynamics (MD). Optimization and computation of the molecules are done by quantum mechanics. The main part of the quantum mechanics relates to the density functional theory (DFT) [15] [16] [17] . So, the geometry of the antagonist medicinal compound esketamine will be optimized using density functional theory method by B3LYP functional at 6-311++G(d,p) level of theory. It is necessary to say that all QM computations are done using Gaussian 03 software. After optimizing the title molecular structure, the stability and reactivity properties of the said compound will be studied using frontier molecular orbitals (FMOs) theory. Also, the physicochemical properties study is done using an online web tool www.swissadme.ca. On the other hand, the analyses of the binding interactions between esketamine and N-methyl-D-aspartate receptors are carried out using molecular virtual docker (MVD) software [11] [12] [13] [14] [15] [16] [17] [18] .
Results and discussion

Esketamine structural, reactivity and stability properties study
Esketamine molecular structure contains one aromatic ring (benzene) and one sextet aliphatic ring (cyclohexanone). Fig. 1 shows its molecular structure. 
Physicochemical descriptors and ADME parameters of the antagonist compound esketamine
In this study, SwissADME web tool was used in order to predict ADME parameters and pharmacokinetic attributes of the molecule under investigation as well as computation of physicochemical descriptors. In drug discovery, ADME analysis of molecular structures is of particular importance in prediction of their drug likeness and relative oral bioavailability [24] . Fig. 4 indicates the predicted physicochemical graph of the title compound. 
Molecular docking analysis of esketamine binding to the NMDA receptors
The survey through previous studies determines the therapeutical effects of Esketamine in treatment-resistant major depressive disorder through glutamate systems [26] . Therefore, the binding of this compound to four NMDA receptor subtypes namely, NR1, NR2A, NR2B and It can be seen from the data of the Considering both internal and external interactions of the compound-NR2A complex, the total energy score of the system is -70.031. The data regarding the compound's interaction with NR2B is presented in Table 6 . It is deduced from the data that the compound-NR2B complex (Fig. 7) is majorly formed via steric interaction with moldock score of -105.410. Overall, the result extracted from molecular docking of esketamine suggests that the compound asserts its pharmacological effects mainly through interactions with NR2B receptors. 
